Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs

International Journal of Oncology

Volumn 49, Issue 1, 2016, Pages 153-163

  Huang, Ying ^a,b   Yang, Xiang ^b,c   Xu, Tianrui ^b   Kong, Qinghong ^b   Zhang, Yaping ^b   Shen, Yuehai ^b   Wei, Yunlin ^b   Wang, Guanlin ^b   Chang, Kwen Jen ^b  

^a Faculty of Environmental Science and Engineering   (China)

^b KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; C FLIP; Cancer therapy; Drug combination; IAPs; TRAIL

Indexed keywords

FLICE INHIBITORY PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; N BENZHYDRYL DECAHYDRO 5 [2 (METHYLAMINO)PROPIONAMIDO] 3 (3 METHYLBUTANOYL) 6 OXOPYRROLO[1,2 A][1,5]DIAZOCINE 8 CARBOXAMIDE; NATURAL PRODUCT; PROCASPASE 8; ROCAGLAMIDE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AZOCINE DERIVATIVE; BENZHYDRYL DERIVATIVE; BENZOFURAN DERIVATIVE; CFLAR PROTEIN, HUMAN; N-BENZHYDRYL-5-(2-(METHYLAMINO)PROPANAMIDO)-3-(3-METHYLBUTANOYL)-6-OXODECAHYDROPYRROLO(1,2-A)(1,5)DIAZOCINE-8-CARBOXAMIDE; TNFSF10 PROTEIN, HUMAN; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; GLIOMA CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SOLID TUMOR; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZOCINES; BENZHYDRYL COMPOUNDS; BENZOFURANS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84978394015     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3525     Document Type: Article

References (53)

1. Tannock IF: Cancer: Resistance through repopulation. Nature 517: 152-153, 2015.
2. Santarpia L, Lippman SM and El-Naggar AK: Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16: 103-119, 2012.
3. Sriraman SK, Aryasomayajula B and Torchilin VP: Barriers to drug delivery in solid tumors. Tissue Barriers 2: e29528, 2014.
4. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
5. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996.
6. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
7. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H and Okumura K: Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7: 94-100, 2001.
8. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ and Ashkenazi A: Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611-620, 2000.
9. Lemke J, von Karstedt S, Zinngrebe J and Walczak H: Getting TRAIL back on track for cancer therapy. Cell Death Differ 21: 1350-1364, 2014.
10. Holland PM: Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev 25: 185-193, 2014.
11. Dyer MJ, MacFarlane M and Cohen GM: Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol 25: 4505-4506, 2007.
12. Koschny R, Walczak H and Ganten TM: The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med Berl 85: 923-935, 2007.
13. Salvesen GS and Duckett CS: IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 3: 401-410, 2002.
14. Fulda S: Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Rev Anticancer Ther 7: 1255-1264, 2007.
15. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, Liu L, Qiu S, Yang CY, Miller R, et al: A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 54: 2714-2726, 2011.
16. Fulda S, Wick W, Weller M and Debatin KM: Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808-815, 2002.
17. Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM and Fulda S: Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 113: 1710-1722, 2009.
18. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Möller P, Gschwend JE, et al: Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 69: 2425-2434, 2009.
19. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, et al: Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195, 1997.
20. Aoudjit F and Vuori K: Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract 2012: 283181, 2012.
21. Safa AR and Pollok KE: Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel) 3: 1639-1671, 2011.
22. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ and Borden EC: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11: 915-923, 2004.
23. Bleumink M, Köhler R, Giaisi M, Proksch P, Krammer PH and Li-Weber M: Rocaglamide breaks TRAIL resistance in HTLV1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression. Cell Death Differ 18: 362-370, 2011.
24. Zhu JY, Giaisi M, Köhler R, Müller WW, Mühleisen A, Proksch P, Krammer PH and Li-Weber M: Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ 16: 1289-1299, 2009.
25. Giaisi M, Kohler R, Fulda S, Krammer PH and Li-Weber M: Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas. Int J Cancer 131: 1003-1008, 2012.
26. Gronthos S, Mankani M, Brahim J, Robey PG and Shi S: Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA 97: 13625-13630, 2000.
27. Zhang YP, Kong QH, Huang Y, Wang GL and Chang KJ: Inhibition of c-FLIP by RNAi enhances sensitivity of the human osteogenic sarcoma cell line U2OS to TRAIL-induced apoptosis. Asian Pac J Cancer Prev 16: 2251-2256, 2015.
28. Ziauddin MF, Yeow WS, Maxhimer JB, Baras A, Chua A, Reddy RM, Tsai W, Cole GW Jr, Schrump DS and Nguyen DM: Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/ TRAIL on cultured thoracic cancer cells through mitochondriadependent caspase activation. Neoplasia 8: 446-457, 2006.
29. Micheau O, Shirley S and Dufour F: Death receptors as targets in cancer. Br J Pharmacol 169: 1723-1744, 2013.
30. Wiezorek J, Holland P and Graves J: Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 16: 1701-1708, 2010.
31. Graves JD, Kordich JJ, Huang TH, Piasecki J, Bush TL, Sullivan T, Foltz IN, Chang W, Douangpanya H, Dang T, et al: Apo2L/ TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 26: 177-189, 2014.
32. Fulda S: Safety and tolerability of TRAIL receptor agonists in cancer treatment. Eur J Clin Pharmacol 71: 525-527, 2015.
33. Sayers TJ: Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 60: 1173-1180, 2011.
34. Menke C, Bin L, Thorburn J, Behbakht K, Ford HL and Thorburn A: Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. Cancer Res 71: 1883-1892, 2011.
35. Daniel PT, Wieder T, Sturm I and Schulze-Osthoff K: The kiss of death: Promises and failures of death receptors and ligands in cancer therapy. Leukemia 15: 1022-1032, 2001.
36. Schneider P, Olson D, Tardivel A, Browning B, Lugovskoy A, Gong D, Dobles M, Hertig S, Hofmann K, Van Vlijmen H, et al: Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 278: 5444-5454, 2003.
37. Wu GS, Burns TF, Zhan Y, Alnemri ES and El-Deiry WS: Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 59: 2770-2775, 1999.
38. van Dijk M, Halpin-McCormick A, Sessler T, Samali A and Szegezdi E: Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways. Cell Death Dis 4: e702, 2013.
39. Jänicke RU, Sprengart ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360, 1998.
40. Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ and Thor AD: Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin-and etoposide-induced apoptosis. Cancer Res 61: 348-354, 2001.
41. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N and Brodeur GM: Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61: 1314-1319, 2001.
42. Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U and Stahel R: Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10: 356-364, 2003.
43. Duiker EW, Meijer A, van der Bilt ARM, Meersma GJ, Kooi N, van der Zee AG, de Vries EG and de Jong S: Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer 104: 1278-1287, 2011.
44. Jia SH, Parodo J, Kapus A, Rotstein OD and Marshall JC: Dynamic regulation of neutrophil survival through tyrosine phosphorylation or dephosphorylation of caspase-8. J Biol Chem 283: 5402-5413, 2008.
45. Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR and Ashkenazi A: Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137: 721-735, 2009.
46. Bellail AC, Olson JJ, Yang X, Chen ZJ and Hao C: A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov 2: 140-155, 2012.
47. Fulda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B and Debatin KM: Sensitization for death receptor-or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20: 5865-5877, 2001.
48. Casciano I, De Ambrosis A, Croce M, Pagnan G, Di Vinci A, Allemanni G, Banelli B, Ponzoni M, Romani M and Ferrini S: Expression of the caspase-8 gene in neuroblastoma cells is regulated through an essential interferon-sensitive response element (ISRE). Cell Death Differ 11: 131-134, 2004.
49. Fulda S and Debatin KM: IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21: 2295-2308, 2002.
50. Crowder RN and El-Deiry WS: Caspase-8 regulation of TRAILmediated cell death. Exp Oncol 34: 160-164, 2012.
51. Soung YH, Lee JW, Kim SY, Sung YJ, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ and Lee SH: Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225-1226delTG in hepatocellular carcinomas. Oncogene 24: 141-147, 2005.
52. Shirley S and Micheau O: Targeting c-FLIP in cancer. Cancer Lett 332: 141-150, 2013.
53. Wajant H, Haas E, Schwenzer R, Muhlenbeck F, Kreuz S, Schubert G, Grell M, Smith C and Scheurich P: Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD). J Biol Chem 275: 24357-24366, 2000.